Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6·4 years

The Lancet

Volumn 374, Issue 9706, 2009, Pages 1975-1985

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN PAPILLOMAVIRUS TYPE 16 HUMAN PAPILLOMAVIRUS TYPE 18 AS04 ADJUVANTED VACCINE; IMMUNOLOGICAL ADJUVANT; PLACEBO; UNCLASSIFIED DRUG; VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CANCER SCREENING; CARCINOGENICITY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS INFECTION;

EID: 71649087760     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61567-1     Document Type: Article

References (37)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., and Wacholder S. Human papillomavirus and cervical cancer. Lancet 370 (2007) 890-907
3. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
4. Muñoz N., Bosch F.X., de Sanjosé S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
5. de Villiers E.-M., Fauquet C., Broker T.R., Bernard H.-U., and zur Hausen H. Classification of papillomaviruses. Virology 324 (2004) 17-27
6. Smith J.S., Lindsay L., Hoots B., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121 (2007) 621-632
7. Bosch F.X., Burchell A.N., Schiffman M., et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26S (2008) K1-K16
8. Stanley M., Lowy D.R., and Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine 24 suppl 3 (2006) S106-S113
9. WHO. Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals (2007). http://www.who.int/reproductivehealth/publications/cancers/IVB_07.05/en/index.htm (accessed Sept 25, 2009).
10. Carter J.J., Koutsky L.A., Wipf G.C., et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174 (1996) 927-936
11. Viscidi R.P., Schiffman M., Hildesheim A., et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13 (2004) 324-327
12. Viscidi R.P., Snyder B., Cu-Uvin S., et al. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 14 (2005) 283-288
13. Ho G., Studentsov Y., Hall C.B., et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 186 (2002) 737-742
14. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol; 110 (suppl 1): S1-10.
15. Garçon N., Chomez P., and Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 6 (2007) 723-739
16. Einstein M.H., Schiller J.T., Viscidi R.P., et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 9 (2009) 347-356
17. Giannini S.L., Hanon E., Moris P., et al. Enhanced humoral and memory B cell immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 (2006) 5937-5949
18. Levie K., Gjorup I., Skinhøj P., and Stoffel M. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scand J Infect Dis 34 (2002) 610-614
19. Pedersen C., Petaja T., Strauss G., et al. Immunization of adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 40 (2007) 564-571
20. Paavonen J., Jenkins D., Bosch F.X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
21. Harper D.M., Franco E.L., Wheeler C.M., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
22. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
23. Descamps D., Hardt K., Spiessens B., et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials. Hum Vaccin 5 (2009) 332-340
24. Gall SA, Teixeira J, Wheeler CM, et al. Substantial impact on pre-cancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine (abstract). In: American Association for Cancer Research Annual Meeting; April 14-18, 2007; Los Angeles, CA (abstr 4900).
25. Pastrana D.V., Buck C.B., Pang Y.-Y., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321 (2004) 205-216
26. Einstein M.H., Baron M., Levin M.J., et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 5 (2009) 705-719
27. Koshiol J., Lindsay L., Pimenta J.M., Poole C., Jenkins D., and Smith J.S. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 168 (2008) 123-137
28. Muñoz N., Bosch F.X., Castellsagué X., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 (2004) 278-285
29. Pirog E.C., Kleter B., Olgac S., et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 157 (2000) 1055-1062
30. Smith H.O., Tiffany M.F., Qualls C.R., and Key C.R. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol Oncol 78 (2000) 97-105
31. Paavonen J., Naud P., Salmerón J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374 (2009) 301-314
32. Villa L.L., Costa R.L., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
33. Banatvala J., Van Damme P., and Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 19 (2000) 877-885
34. David M.-P., Van Herck K., Hardt K., et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol 115 suppl 3 (2009) S1-S6
35. Kemp T.J., García-Piñeres A., Falk R.T., et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 26 (2008) 3608-3616
36. Nardelli-Haefliger D., Wirthner D., Schiller J.T., et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 95 (2003) 1128-1137
37. Joura E.A., Kjaer S.K., Wheeler C.M., et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26 (2008) 6844-6851